Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Osiris Therapeutics, Inc.    OSIR   US68827R1086

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/26/2015 02/27/2015 03/02/2015 03/03/2015 03/04/2015 Date
17.34(c) 17.27(c) 17.38(c) 17.52(c) 17.8(c) Last
156 432 78 366 85 785 177 318 148 515 Volume
-0.80% -0.40% +0.64% +0.81% +1.60% Change
More quotes
Company
Osiris Therapeutics, Inc. is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets.The company operates its business through two segments: Therapeutics and Biosurgery segment.The... 
More about the company
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | OSIR | US68827R1086 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 59,4 M
EBIT 2014 2,54 M
Net income 2014 1,99 M
Debt 2014 -
Yield 2014 -
Sales 2015 87,7 M
EBIT 2015 11,3 M
Net income 2015 14,3 M
Debt 2015 -
Yield 2015 -
PER 2014 296,67
PER 2015 43,41
Capi. / Sales 2014 10,3x
Capi. / Sales 2015 6,97x
Capitalization 611 M
More Financials
Latest news on OSIRIS THERAPEUTICS, INC.
02/19 OSIRIS THERAPEUTICS : Sets Fourth Quarter Results Conference Call
02/16 OSIRIS THERAPEUTICS : Schedules Fourth Quarter Results Conference Call
02/11 OSIRIS THERAPEUTICS : Announces Fourth Quarter and Full Year 2014 Financial Resu..
01/02 OSIRIS THERAPEUTICS : Partners with Stryker
01/02 OSIRIS THERAPEUTICS : Joins Forces with Stryker for Marketing ' Viable Bone Matr..
01/01 OSIRIS THERAPEUTICS : Announces a Strategic Partnership with Stryker for Marketi..
2014 OSIRIS THERAPEUTICS : Entry into a Material Definitive Agreement, Regulation FD ..
2014 OSIRIS THERAPEUTICS : Announces a Strategic Partnership with Stryker for Marketi..
More news
Sector news Bio Therapeutic Drugs
03:30a AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
03:30a AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
01:25a JOHNSON & JOHNSON : What the other papers say this morning
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF